Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 42

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 42
---
 Report on Form 8-K,in accordance with Commission rules:

| • |     | The description of our common stock contained in our registration statement on Form                                                              
 8-A (File No. 001-40908) filed with the Commission on October 13, 2021, including any amendment or report filed for the purpose of updating such 
 description.                                                                                                                                     |

Upon request, either orally or in writing, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, a copy of the documents incorporated by reference into this prospectus but not delivered with the prospectus. You may request a copy of these filings and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus, at no cost, by writing to us at the following address: MiNK Therapeutics, Inc., 149 Fifth Avenue, Suite 500, New York, New York 10010; Attention: Investor Relations. 23

LEGAL MATTERS

Unless the applicable prospectus supplement indicates otherwise, the validity of any securities offered from time to time by this prospectus will be passed
upon for us by Ropes & Gray LLP, Boston, Massachusetts. The validity of any securities will be passed upon for any underwriters or agents by counsel that we will name in the applicable prospectus supplement.

EXPERTS

The
consolidated financial statements of MiNK Therapeutics, Inc. as of December 31, 2021 and 2020 and for the years then ended, have been so incorporated by reference herein in reliance upon the report of KPMG LLP, independent registered public
accounting firm, incorporated by reference herein and upon the authority of said firm as experts in accounting and auditing.

24

Up to $50,000,000 of Common Stock

Prospectus Supplement

Sole Sales Agent

B. RILEY SECURITIES

July 15, 2025